Eli Lilly (NYSE: LLY) has released updated data from its Phase I/II clinical trial evaluating olomorasib.
The data relate to use of the KRAS blocker both as a monotherapy for KRAS G12C-mutant advanced solid tumors and in combination with Merck & Co's (NYSE: MRK) checkpoint blocker Keytruda (pembrolizumab), for advanced non-small cell lung cancer.
There is a wave of interest in KRAS blockers, an approach which targets a mutation present in lung cancers but also certain colorectal and pancreatic cancers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze